MedICAL ADVOCATES
Children
  ARV/HAART

ARV Guidelines 
 ARV Drug Index
ARV Drug Classes
 General Reports
 Post-Exposure Prophylaxis
Safety
 Immune Response
Tolerability
Pharmacokinetics
 Adverse Events
 Adherence
Resistance		 Efficacy  
Treatment Strategies 
Treatment Failure
Quality of Life
 National Studies 



 
Pediatric HIV Drug Main Page Pediatric HIV Main Page Home Page
Last Update:  August 23, 2008  
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
          Journal Papers, Abstracts, and Commentaries
 
 
Humoral and Cellular Response to Influenza Vaccine in HIV-Infected Children With Full Viroimmunologic
Response to Antiretroviral Therapy.
 Viganò A, Zuccotti GV, Pacei M, et al 
J Acquir Immune Defic Syndr. 2008 Jun 9.
 Abstract
 
Current and Future Antiretroviral Treatment Options in Paediatric HIV Infection.
Giaquinto C, Morelli E, Fregones F, et al
Clin Drug Investig. 2008;28(6):375-97.
 Abstract
 
Pediatric HIV infection: the state of antiretroviral therapy.
 McKellar MS, Callens SF, Colebunders R.
Expert Rev Anti Infect Ther. 2008 Apr;6(2):167-180.
 Abstract
 
Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they
mean?
 Lee KJ, Shingadia D, Pillay D, et al 
Antivir Ther. 2007;12(6):949-56.
 Abstract
 
Pediatric HIV-1-Specific Cytotoxic T-Lymphocyte Responses Suggesting Ongoing Viral
Replication Despite Combination Antiretroviral Therapy.
 Ching N, Yang OO, Deville JG, et al 
Pediatr Res. 2007 Apr 5;
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Impact on Weight and Height With the Use of HAART in HIV-Infected Children.
 Guillen S, Ramos JT, Resino R, et al 
Pediatr Infect Dis J. 2007 Apr;26(4):334-338.
Abstract
 
Effectiveness of Early Initiation of Protease-Sparing Regimen in HIV-1 Vertically
Infected Infants
 Van der Linden D, Hainaut M, et al
Pediatr Infect Dis J. 2007 Apr;26(4):359-361.
 Abstract
 
Increasing Antiretroviral Drug Access for Children With HIV Infection.
 [No authors listed]  
Pediatrics. 2007 Apr;119(4):838-45.
 Abstract
 
Initiating Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type
1-Infected Children in Europe and the United States: Comparing Clinical Practice to
Guidelines and Literature Evidence.
Verweel G, Saavedra-Lozano J, van Rossum AM, et al 
Pediatr Infect Dis J. 2006 Nov;25(11):987-994.
Abstract
 
HIV-1-infected children on HAART: Immunologic features of three different levels of viral
suppression.
Zaccarelli-Filho CA, Ono E, et al 
Cytometry B Clin Cytom. 2006 Oct 13;
 Abstract
 
Long-Term Decay of the HIV-1 Reservoir in HIV-1-Infected Children Treated with
Highly Active Antiretroviral Therapy.
Zanchetta M, Walker S, Burighel N, et al 
J Infect Dis. 2006 Jun 15;193(12):1718-27
Abstract
 
Cytomegalovirus-Specific Cell-Mediated Immunity in HIV-Infected Children on HAART.
Weinberg A, Wiznia AA, Lafleur BJ, et al 
AIDS Res Hum Retroviruses. 2006 Mar;22(3):283-8.
 Abstract
 
Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type
1-infected children: 6 years of follow-up.
Resino S, Resino R, Micheloud D, et al 
Clin Infect Dis. 2006 Mar 15;42(6):862-9.
Abstract
 
Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active
antiretroviral therapy.
Urschel S, Ramos J, Mellado M,
AIDS. 2005 Dec 2;19(18):2103-2108.
 Abstract
 
Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27- T cells in
HIV-1-infected children.
Bekker V, Bronke C, Scherpbier HJ, et al
AIDS. 2005 Jul 1;19(10):1025-1034.
 Abstract
 
Children with HIV: improved mortality and morbidity with combination antiretroviral therapy.
Foster C, Lyall EH. 
Curr Opin Infect Dis. 2005 Jun;18(3):253-9
 Abstract

Treatment of human immunodeficiency virus (HIV) in children using antiretroviral drugs.
Anabwani GM, Woldetsadik EA, Kline MW.
Semin Pediatr Infect Dis. 2005 Apr;16(2):116-24
 Abstract
 
Two-Year Clinical and Immune Outcomes in Human Immunodeficiency Virus-Infected
Children Who Reconstitute CD4 T Cells Without Control of Viral Replication After
Combination Antiretroviral Therapy.
 Ghaffari G, Passalacqua DJ, Caicedo JL, et al   
Pediatrics. 2004 Oct 18
Abstract
 
Rapid Human Immunodeficiency Virus Decay in Highly Active Antiretroviral Therapy
(HAART)-Experienced Children after Starting Mega-HAART.
 Plipat N, Ruan PK, Fenton T, Yogev R.
J Virol. 2004 Oct;78(20):11272-5
 Abstract
 
Response to superantigen stimulation in peripheral blood mononuclear cells from
children perinatally infected with human immunodeficiency virus and receiving highly
active antiretroviral therapy.
 McCloskey TW, Haridas V, Pontrelli L, Pahwa S. 
Clin Diagn Lab Immunol. 2004 Sep;11(5):957-62.
 Abstract
 
Response to highly active antiretroviral therapy varies with age: the UK and Ireland
Collaborative HIV Paediatric Study.
 For the Collaborative HIV Paediatric Study (CHIPS) Steering Committee.
AIDS. 2004 Sep 24;18(14):1915-1924.
 Abstract
 
Decrease in Hospitalization and Mortality Rates among Children with Perinatally
Acquired HIV Type 1 Infection Receiving Highly Active Antiretroviral Therapy.
 Viani RM, Araneta MR, Deville JG, Spector SA. et al 
Clin Infect Dis. 2004 Sep 1;39(5):725-31.
 Abstract
 
HIV-infected children with moderate/severe immune-suppression: changes in the i
mmune system after highly active antiretroviral therapy.
Resino S, Galan I, Perez A, et al  
Clin Exp Immunol. 2004 Sep;137(3):570
 Abstract
 
PENTA guidelines for the use of antiretroviral therapy, 2004.
Sharland M, Blanche S, Castelli G, et al 
HIV Med. 2004 Jul;5(S2):61-86.
Abstract

Extensive Implementation of Highly Active Antiretroviral Therapy Shows Great
Effect on Survival and Surrogate Markers in Vertically HIV-Infected Children.
Resino S, M Feminine Bellon J, et al 
Clin Infect Dis. 2004 Jun 1;38(11):1605-12.
 Abstract
 
Newer treatments for HIV in children.
McKinney Jr RE, Cunningham CK.et al.
Curr Opin Pediatr. 2004 Feb;16(1):76-9.\
 Abstract
 
Pharmacology considerations for antiretroviral therapy in human immunodeficiency
 virus (HIV)-infected children.
Hoody DW, Fletcher CV
Semin Pediatr Infect Dis. 2003 Oct; 14(4):
 Abstract

Evaluation of multiple drug therapy in human immunodeficiency virus-infected
pediatric patients.
King JR, Acosta EP, Chadwick E, et al.  
Pediatr Infect Dis J 2003 Mar;22(3):239-244
Abstract
 

  
          Conference Reports, Abstracts, and Posters 
 
 
CONFERENCE PDF POSTER
 Partial Restoration of Mitochondrial DNA Content in Perinatally HIV-infected Pediatric
Patients after Planned Interruption of HAART
 A Noguera, C Moren, E Corrales, et al
(15 CROI)
 PDF Poster     Abstract
 
Gene Expression and Viral Production in HIV-suppressed and HIV-non-suppressed Perinatally
HIV-infected Children on HAART
 Mi Qin, K Nielsen-Saines, J Deville, et al
(14 CROI)
 Abstract
 
Formulation, dosing and ART strategies for children with HIV infection
D Gibb
[8th Int Congress on Drug Therapy in HIV Infection]
 Abstract
 
POSTER
Preservation of CD4 T Cell Production despite High HIV Replication in Children and Adolescents
Receiving PI-containing ART
C Rodriguez, L Yin, S Koch, et al
 13 CROI)
 PDF Poster     Abstract

POSTER
Serologic Responses to Recall and Neoantigens in Severely Immunocompromised HIV-infected
Children Initiating HAART
M Rigaud, W Borkowsky, P Muressan,  wt al
(13 CROI)
 PDF Poster     Abstract
Post-Exposure Prophylaxis
 
          Journal Papers, Abstracts, and Commentaries
 
 
A pilot study of health beliefs and attitudes concerning measures of antiretroviral adherence among
prisoners receiving directly observed antiretroviral therapy.
White BL, Wohl DA, Hays RD, et al; 
AIDS Patient Care STDS. 2006 Jun;20(6):408-17.

Postexposure prophylaxis in children and adolescents for nonoccupational
exposure to human immunodeficiency virus.
Havens PL
 Pediatrics. 2003 Jun;111(6 Pt 1):1475-89.
Abstract

  
Safety
 
          Journal Papers, Abstracts, and Commentaries
 
  Drug safety during pregnancy and in infants. Lack of mortality related to
mitochondrial dysfunction among perinatally HIV-exposed children in pediatric
HIV surveillance.
Lindegren ML, Rhodes P, Gordon L, et al.
Ann N Y Acad Sci 2000 Nov;918:222-35
Abstract
Tolerability
 
          Journal Papers, Abstracts, and Commentaries     
 
  Tolerabilities of Antiretrovirals in Paediatric HIV Infection.
Avi Lemberg D, Palasanthiran P, Goode M, Ziegler JB.
Drug Saf 2002;25(14):973-91
 Abstract		  
Pharmacokinetics
 
          Journal Papers, Abstracts, and Commentaries     
 
  Pharmacokinetics of Antiretroviral Therapy in HIV-1-Infected Children
Fraaij PL, van Kampen JJ, Burger DM, de Groot R. 
Clin Pharmacokinet. 2005;44(9):935-956.
Abstract		  
Immune Response
 
          Journal Papers, Abstracts, and Commentaries   
  
 
LOW IMMUNOLOGIC RESPONSE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
IN NAIVE VERTICALLY HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-INFECTED
CHILDREN WITH SEVERE IMMUNODEFICIENCY.
Resino S, Alvaro-Meca A, de Jose MI, et al   
Pediatr Infect Dis J. 2006 Apr;25(4):365-368.
 Abstract
 
Immunologic Function and Virologic Suppression Among Children With Perinatally
 Acquired HIV Infection on Highly Active Antiretroviral Therapy.
Rutstein RM, Gebo KA, Flynn PM, et al
Med Care. 2005 Sep;43(9 suppl):15-22.
 Abstract

Immunological Response to Highly Active Antiretroviral Therapy in Children with Clinically
Stable HIV-1 Infection.
Rosenblatt HM, Stanley KE, Song LY, et al   
J Infect Dis. 2005 Aug 1;192(3):445-455.
Abstract
 
          Conference Reports, Abstracts, and Posters 
 
 
CONFERENCE PDF POSTER
 HIV-1 Env V1V2-length Polymorphism Predicts Combination ART Outcome in HIV-infected
Children
L Yin, S McCready, A Lowe, et al
 (14 CROI)
PDF Poster     Abstract

Predictors of the response to HAART in HIV-1 infected children
R Bologna, C Rocco, D Mecikovsky, et al
 (15IAC)
 Abstract
Resistance
 
          Journal Papers, Abstracts, and Commentaries
 
 
HIV-1 DRUG RESISTANCE IN HIV-1-INFECTED CHILDREN IN THE UNITED KINGDOM
FROM 1998 TO 2004.
 Chakraborty R, Smith CJ, Dunn D, et al 
Pediatr Infect Dis J. 2008 Mar 27
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.
 Delaugerre C, Warszawski J, Chaix ML, et al 
J Med Virol. 2007 Jul 2;79(9):1261-1269
 Abstract
 
Emergence of human immunodeficiency virus type 1 variants containing the Q151M complex in
children receiving long-term antiretroviral chemotherapy.
 Harada S, Hazra R, Tamiya S, et al
Antiviral Res. 2007 Mar 21;
 Abstract
 
HIV-1 drug resistance in French infected-children: from newborn to adolescent.
 Delaugerre C, Chaix ML, Warszawski J, et al 
Arch Pediatr. 2007 Feb 5
 Abstract

Antiretroviral drug resistance among HIV-1 infected children failing treatment.
Mullen J, Leech S, O’Shea S, et al. J
Med Virol 2002 Nov;68(3):299-304
 Abstract

Impact of Human Immunodeficiency Virus Type 1 Subtypes on Virologic
Response and Emergence of Drug Resistance among Children in the Paediatric
European Network for Treatment of AIDS (PENTA) 5 Trial.
Pillay D, Walker AS, Gibb DM,  
J Infect Dis 2002 Sep 1;186(5):617-25
 Abstract

Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV
resistance, and clinical manifestations of encephalopathy.
McCoig C, Castrejon MM, Castano E, et al
J Pediatr 2002 Jul;141(1):36-44
 Abstract

Analysis of human immunodeficiency virus type 1 drug resistance in children
receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine,
nelfinavir, or ritonavir
(Pediatric AIDS Clinical Trials Group 377).Eshleman SH, et al
J Infect Dis 2001 Jun 15;183(12):1732-8
Abstract

  

          Conference Reports, Abstracts, and Posters 

 
POSTER
High Frequency of Mutations Associated to Antiretroviral Drug Resistance in Recently
Diagnosed HIV-infected Children
M Vignoles , S González-Ayala, G Barboni, et al
(13 CROI)
 PDF Poster     Abstract

Antiretroviral Drug Resistance in French Treated HIV-1-Infected Children
C. DELAUGERRE, J. WARSZAWSKI , M. CHAIX, et al 
(45 ICAAC}
 Abstract
Adherence
 
          Journal Papers, Abstracts, and Commentaries
 
 
Assessment of Adherence to Antiretroviral Therapy in Perinatally HIV-Infected Children and Youth Using
Self-Report Measures and Pill Count.
Farley JJ, Montepiedra G, Storm D, et al  
J Dev Behav Pediatr. 2008 Aug 13
 Abstract
 
The Role of Cognitive Functioning in Medication Adherence of Children and Adolescents
with HIV Infection.
 Malee K, Williams PL, Montepiedra G, et al
J Pediatr Psychol. 2008 Jul 22.
Abstract
 
Adherence to Antiretroviral Therapy for Pediatric HIV Infection: A Qualitative Systematic
Review With Recommendations for Research and Clinical Management.
 Simoni JM, Montgomery A, Martin E, et al  
Pediatrics. 2007 May 28;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy of a Pill-Swallowing Training Intervention to Improve Antiretroviral Medication
Adherence in Pediatric Patients With HIV/AIDS.
 Pediatrics. 2007 Mar 12;
 Abstract
 
Predictors of adherence to antiretroviral medications in children and adolescents with
HIV infection.
 Williams PL, Storm D, Montepiedra G, et al  
Pediatrics. 2006 Dec;118(6):e1745-57.
Abstract
 
Predictors of Adherence to Antiretroviral Medications in Children and Adolescents With
HIV Infection.
Williams PL, Storm D, Montepiedra G, et al
Pediatrics. 2006 Nov 13;
Abstract
 
Caregiver Psychosocial Characteristics and Children’s Adherence to Antiretroviral Therapy.
Marhefka SL, Tepper VJ, Brown JL, Farley JJ. 
AIDS Patient Care STDS. 2006 Jun;20(6):429-37.
 Abstract
 
Brief Report: Assessing Adherence to Pediatric Antiretroviral Regimens Using the
24-Hour Recall Interview.
Marhefka SL, Tepper VJ, Farley JJ, et al 
J Pediatr Psychol. 2006 Mar 2;
Abstract

Use of Multisystemic Therapy to Improve Antiretroviral Adherence and Health Outcomes
in HIV-Infected Pediatric Patients: Evaluation of a Pilot Program.
Ellis DA, Naar-King S, Cunningham PB, Secord E.
AIDS Patient Care STDS. 2006 Feb;20(2):112-21
 Abstract

Pediatric adherence: Perspectives of mothers of children with HIV.
Wrubel J, Tedlie Moskowitz J, Anne Richards T, et al
Soc Sci Med. 2005 Jun 1;
 Abstract
 
Measuring adherence to treatment of paediatric HIV/AIDS.
Naar-King S, Frey M, Harris M, Arfken C.  
AIDS Care. 2005 Apr;17(3):345-9
 Abstract
 
Integrating Adherence to Highly Active Antiretroviral Therapy Into Children’s Daily
Lives: A Qualitative Study.
 Hammami N, Nostlinger C, Hoeree T, et al.
Pediatrics. 2004 Nov;114(5):e591-7.
 Abstract
 
Nonadherence with pediatric human immunodeficiency virus therapy as
medical neglect.
Roberts GM, Wheeler JG, Tucker NC, 
Pediatrics. 2004 Sep;114(3):E346-53.
 Abstract

Adherence to prescribed antiretroviral therapy in human immunodeficiency
virus-infected children in the PENTA 5 trial.
Gibb DM, Goodall RL, Giacomet V, et al.
Pediatr Infect Dis J 2003 Jan;22(1):56-62
 Abstract
 
Adherence to combination antiretroviral treatment in children.
Pontali E, Feasi M, Toscanini F
HIV Clin Trials 2001 Nov-Dec;2(6):466-473
 Abstract

          Conference Reports, Abstracts, and Posters 

 
Improving treatment compliance in HIV infected children
 Vaudre G, Dollfus C, Tabone MD, Leverger G
(4th IAS Conference)
 Abstract
 
The measurement of pediatric adherence to antiretroviral therapy: a systematic review
 Vreeman R, Wiehe S, Nyandiko Mokoya W, et al
 (4th IAS Conference)
 Abstract
 
Orphan status and pediatric anti-retroviral therapy adherence in a resource-poor setting
 Wiehe SE, Vreeman RC, Musick BS, et al
 (4th IAS Conference)
 Abstract

Impact of Adherence for the Successful Treatment of Children with AIDS
 M.M. CASTREJON, O. DE SUMAN, J. NIETO, et al  
(45 ICAAC}
 Abstract
Efficacy
 
        Journal Papers, Abstracts, and Commentaries
 
 
Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
 Prendergast A, Mphatswe W, Tudor-Williams G, et al 
AIDS. 2008 Jul 11;22(11):1333-43.
 Abstract
 
Long-Term Effects of Highly Active Antiretroviral Therapy on CD4(+) Cell Evolution among
Children and Adolescents Infected with HIV: 5 Years and Counting.
 Patel K, Hernán MA, Williams PL, et al
Clin Infect Dis. 2008 Apr 2
 Abstract
 
Clinical Outcomes Improve with Highly Active Antiretroviral Therapy in Vertically
HIV Type-1-Infected Children.
Resino S, Resino R, Bellon JM, et al 
Clin Infect Dis. 2006 Jul 15;43(2):243-52.
 Abstract
 
Immunologic Function and Virologic Suppression Among Children With Perinatally
Acquired HIV Infection on Highly Active Antiretroviral Therapy.
Rutstein RM, Gebo KA, Flynn PM, et al
Med Care. 2005 Sep;43(9 suppl):15-22.
 Abstract
 
Sustained Viral Suppression and Immune Recovery in HIV Type 1-Infected Children
after 4 Years of Highly Active Antiretroviral Therapy.
Fraaij PL, Verweel G, van Rossum AM,  et al 
Clin Infect Dis. 2005 Feb 15;40(4):604-8.
Abstract
 
A trial of three antiretroviral regimens in HIV-1-infected children.
Luzuriaga K, McManus M, Mofenson L, et al  
N Engl J Med. 2004 Jun 10;350(24):2471-80.
 Abstract  

Efficacy and toxicity of antiretroviral therapy using 4 or more agents: application of a
strategy for antiretroviral management in human immunodeficiency virus-infected 
children.
Melvin AJ, Lewis PF, Mohan KM,
Arch Pediatr Adolesc Med 2002 Jun;156(6):568-73
 Abstract  

Treatment With Highly Active Antiretroviral Therapy in Human Immunodeficiency
Virus Type 1-Infected Children Is Associated With a Sustained Effect on Growth.
Verweel G, van Rossum AM, Hartwig NG, et al.  
Pediatrics 2002 Feb;109(2):E25-E25
 Abstract  

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir,
or ritonavir for pretreated children infected with human immunodeficiency virus
type 1.
Krogstad P, Lee S, Johnson G, Stanley K, et al.
 Clin Infect Dis 2002 Apr 1;34(7):991-1001
 Abstract

 		 

      Conference Reports, Abstracts, and Posters 

 
Does Early Treatment Provide Long-term Benefit in HIV-1-infected Infants? 5-Year Outcomes
in Children Treated before 3 Months of Age in the PENTA 7 Trial
 A Compagnucci, Y Saïdi, L Harper et al
(14 CROI)
 Abstract
 
Delayed Clearance of Latently Infected CD4+ T Cells in HIV-1-infected Infants Initiating HAART
Younger than 6 Months of Age
 D Persaud, C Ziemniak, K Ferguson, et al
(14 CROI)
 Abstract
 
Three year outcomes in children treated with HAART before 3 months of age in the
PENTA 7 trial
A Compagnucci, Y Saïdi, L Harper,  al
 (15IAC)
 Abstract
 
Comparison of TCR CDR3 Length Distribution in CD4 and CD8 T Cell Naive and
Memory Subpopulations in Healthy and HIV-infected Children before and after ART
Li Yin , Z Kou , M Goodenow ,   J Sleasman
(11 CROI)
 Abstract
 
Vigorous HIV-1-specific CTL Responses in Long-term Survivors of Neonatal HIV-1
Infection
Otto Yang, S Kilpatrick, J Church , et al;
(11 CROI)
 Abstract

Outcomes of Treatment Interruption in HIV-infected Children
 A Alimenti, D Burdge, D Khoo, et al
(11 CROI)
 Abstract
 
Efficacy of NNRTI-based HAART among Antiretroviral Naive HIV-infected
Children in Thailand: 24-week Result
T Puthanakit, N Akarathum, S Kanjanavanit, et al
 (11 CROI)
 Abstract
 
Treatment Failure
 

        Journal Papers, Abstracts, and Commentaries

  Persistently high IgA serum levels are a marker of immunological or virological failure of combined
antiretroviral therapy in children with perinatal HIV-1 infection.
Chiappini E, Galli L, Tovo PA, et al 
Clin Exp Immunol. 2005 May;140(2):320
 Abstract
Quality of Line
 

        Journal Papers, Abstracts, and Commentaries

  Persistently high IgA serum levels are a marker of immunological or virological failure of combined
antiretroviral therapy in children with perinatal HIV-1 infection.
Chiappini E, Galli L, Tovo PA, et al 
Clin Exp Immunol. 2005 May;140(2):320
 Abstract

   

Pediatric HIV Drug Main Page Pediatric HIV Main Page Home Page

Photographer: Lutheran World Relief  Photo courtesy of M/MC Photoshare at www.jhuccp.org/mmc and
is  protected by current copyright law 
 ARV/HAART